EMEA’s CHMP Recommends Approval For Avastin In Kidney Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Renal cell cancer would be the fourth indication gained in the EU for the VEGF-inhibitor; Genentech plans to submit an sBLA for kidney cancer in 2008.